Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
VANCOUVER, BC – May 14, 2024 – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has
May 14, 2024
